Searchable abstracts of presentations at key conferences in endocrinology

ea0029p190 | Bone & Osteoporosis | ICEECE2012

Efficacy, safety and adherence to treatment of teriparatide: an observational study

Franceschetti P. , Ambrosio M. , Zatelli M. , Tommasin T. , Bianchi S. , Lupo S. , Corte R La , Uberti E degli

Teriparatide is a skeletal anabolic drug that represents the first and new class of bone anabolic agents able to increase bone formation, bone mineral density and strength. Several studies demonstrated the efficacy of this drug in post-menopausal and glucocorticoid-induced osteoporosis, but few data are available on the effects of the drug in long-term therapy in humans, so far.We analyzed a population of 135 women in post-menopausal age treated with ter...

ea0070aep744 | Pituitary and Neuroendocrinology | ECE2020

Pasireotide-induced hyperglycemia and efficacy of antidiabetic treatments in patients with acromegaly: Evaluation of two referral centers

F.S. Grasso Ludovica , Chiloiro Sabrina , Pirchio Rosa , Giampietro Antonella , Auriemma Renata S. , Bianchi Antonio , De Martino Maria Cristina , Negri Mariarosaria , Colao Annamaria , Pontecorvi Alfredo , De Marinis Laura , Pivonello Rosario

Pasireotide (PAS) has a safety profile similar to first-generationsomatostatin analogues (SSA), except for a higher frequency of hyperglycaemia-related adverse events (AEs). However, consensus on the best management of PAS-induced hyperglycaemia in acromegalic patients has still to be defined. The current study aims at investigating the effects of long-term PAS treatment on glucose metabolism, by evaluating the clinical management of hyperglycemia-relatedAEs in acromegalic pat...